DB17231InvestigationalCell transplant therapies
Orvacabtagene autoleucel: Overview.
- Mechanism
- Curator reviewed
Pharmacologically active on Tumor necrosis factor receptor superfamily member 17
- Also known as
- JCARH125 CONSISTS OF HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CD4+ CD8+ T CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL V · orva-cel
- Code names
- ET-140 · JCARH-125
Resolves to
Compound
Targets
What you can answer from here — as of July 08, 2026
Which drugs share a target with Orvacabtagene autoleucel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account